Skip to content
Screener

R&D at other companies

Abbott logo
AbbottABT
$892M+23.0%
Guardant Health logo
Guardant HealthGH
$91.04M+2.8%
Natera, Inc. logo
Natera, Inc.NTRA
$228.07M+55.8%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$52.64M+26.5%
Myriad Genetics logo
Myriad GeneticsMYGN
$27.1M-1.5%
Personalis, Inc. logo
Personalis, Inc.PSNL
$14.54M+15.0%

Segments

By segment

See full
Reportable Segment$42.46M+0.7%

Other financials

Income statement

See full
Revenue$44.7M+25.7%
Operating income-$173.8M-9.4%
Net income-$110.2M+3.3%
EPS (diluted)-$2.56+19.5%

Balance sheet

See full
Cash & equivalents$62.6M-52.1%
Total debt$91.3M+46.9%
Total equity$2.5B+9.9%
Total assets$2.8B+5.2%

Cash flow

See full
Operating cash flow-$80.7M-4.9%
CapEx$432.0K+17.1%
Free cash flow-$81.2M-4.9%

Valuation

See full
Market cap$2.72B+129%
Enterprise value$2.75B+145%
P/S16.5×+7.6×

Profitability

See full
Operating margin-338.4%-74.4pp
Net margin-236.9%-52.1pp
FCF margin-179.2%-46.7pp

Returns & leverage

See full
Return on equity-16.1%-1.3pp
Debt / equity0.0×
Current ratio10.9×+1.7×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: GRAIL, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054307
Line itemThree Months Ended / June 30,2026Three Months Ended / June 30,2025Six Months Ended / June 30,2026Six Months Ended / June 30,2025
Cost of screening revenue (exclusive of amortization of intangible assets)23,34719,34644,59136,469
Cost of development services revenue4345018101,672
Cost of revenue — amortization of intangible assets33,47233,47266,94466,944
Research and development47,42946,62695,450100,251
Sales and marketing37,65728,53968,32563,518
General and administrative50,70837,91493,47782,988
Intangible and other assets impairment25,42328,00025,42328,000
Total costs and operating expenses218,470194,398395,020379,842

Item 1. Financial Statements

FAQ

What is GRAIL, Inc.'s R&D?
GRAIL, Inc. (GRAL) reported R&D of $47.43M in Q2 2026.
How has GRAIL, Inc.'s R&D changed year-over-year?
GRAIL, Inc.'s R&D increased by 1.7% year-over-year, from $46.63M to $47.43M.
What is the long-term trend for GRAIL, Inc.'s R&D?
Over 3 years (2022 to 2025), GRAIL, Inc.'s R&D has grown at a -15.9% compound annual growth rate (CAGR), from $329.58M to $195.79M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about GRAIL, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude